(RTTNews) - Stereotaxis (STXS) said it has received FDA 510(k) clearance for the Synchrony system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony's 55 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab. It is made available with SynX, a cloud-based HIPAA and GDPR-compliant app that allows for secure remote connectivity, collaboration, recording, and monitoring of the cath lab.
Stereotaxis reiterated its guidance of over $3 million in revenue in the current year from Synchrony systems placed independent of robotic systems.
In pre-market trading on NYSE American, Stereotaxis shares are up 5.8 percent to $2.0.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
